Abstract. The major obstacle to tumor chemotherapy is drug resistance. In the present study, we investigated the characteristics of FaDu cells (a hypopharyngeal carcinoma cell line) with multidrug resistance (MDR) induced by Taxol. The resistant cell line, FaDu/T, was grown by exposing normal FaDu cells to escalating concentrations of Taxol stepwise for over 12 months. The multidrug resistant sensitivities of the FaDu/T cells to cisplatin (DDP), 5-fluorouracil (5-FU), doxorubicin (Dox) and vincristine (VCR) were investigated by methyl-thiazolyl-tetrazolium (MTT) assay. Cell apoptosis was measured by acridine orange and Hoechst 33342/propidium iodide double staining. Cell cycle distribution and the cell apoptosis index were quantified using flow cytometry. Reverse transcription-polymerase chain reaction (RT-PCR) was conducted to determine the mRNA levels of the MDR-related genes MDR1/ ABCB1 and BCRP/ABCG2. Western blotting was used to assay the expression of MDR1/ABCB1 and BCRP/ABCG2 and the apoptosis-related proteins caspase-3, Bcl-2 and Bax. Compared with the FaDu cells, the drug resistance of FaDu/T cells to DDP, 5-FU, Dox and VCR was increased 8.99-, 21.96-, 31.42-and 10.00-fold, respectively. The percentages of FaDu/T cells in the G0/G1 and G2/M phases were increased while the cell percentage in the S phase decreased as compared with the percentages of FaDu cells. The anti-apoptotic ability increased prominently, as the index of apoptosis decreased. Furthermore, caspase-3, Bcl-2 and Bax expression was altered accordingly to resist apoptosis in the FaDu/T cells. MDR1/ABCB1 expression increased significantly at both the mRNA and protein levels, while BCRP/ABCG2 expression appeared to inversely affected, i.e. decreased, in a concentration-dependent manner. These findings may provide theoretical support for the prevention of MDR in clinical cancer chemotherapy.
Introduction
Hypopharyngeal carcinoma, one of the most common malignancies in the head and neck region, results in substantial morbidity and mortality annually. Despite the fact that multimodal approaches have been applied to treat this tumor, the survival rate has not considerably improved during the last two decades (1, 2) . Traditionally, the main treatment option for primary hypopharyngeal carcinoma is surgical resection (3) . This strategy, however, has evolved from the point of view of pure treatment to maximum preservation of hypopharyngeal function, laying emphasis upon the quality of life of these patients. Thus, the standard approach for treatment for these patients is still chemotherapy.
A large number of chemotherapeutic agents are currently in use. Paclitaxel (Taxol ® ) was first approved by the Food and Drug Administration (FDA) for the treatment of refractory ovarian cancer in 1992 but demonstrated activity against head and neck squamous cell carcinoma (HNSCC) (4) . Yet, the effect of Taxol for HNSCC is still far from satisfactory. An important limitation is the occurrence of multidrug resistance (MDR), by which cancer cells escape the toxic effect of most commonly used cancer drugs in spite of their different chemical structure and different mechanism of intracellular activity (5) . Drug concentrations targeted to cells decrease and the sensitivity of cells decline, both of which lead to chemotherapeutic failure and limited clinical effect of chemotherapy. Thus, elucidation of the underlying molecular mechanisms leading to MDR and therapy failure is crucial (6) .
With the aim to elucidate the mechanism of MDR, we carried out the present study using the human hypopharyngeal carcinoma cell line FaDu. A multidrug resistant cell line to Taxol (FaDu/T) was established by exposing normal FaDu cells to escalating concentrations of Taxol stepwise for over 12 months. The main characteristics between the FaDu and FaDu/T cells were investigated. Our results showed that, compared with FaDu cells, the percentage of FaDu/T cells in the G0/G1 phase and their anti-apoptotic ability were both increased. Expression of caspase-3, Bcl-2 and Bax was altered accordingly to resist apoptosis in the FaDu/T cells. Multidrug resistance-related genes MDR1/ABCB1 increased and BCRP/ ABCG2 decreased to counteract the Taxol toxicity in FaDu/T cells. These findings may provide theoretical support for the prevention of MDR in clinical cancer chemotherapy. 4 /ml) subcultured in a 96-well cluster (Corning, USA) were treated with different concentrations of Dox, VCR, 5-FU and DDP for 72 h. MTT (5 mg/ml, 20 µl) was added to each well 4 h prior to the indicated time points. After 4-h of incubation at 37˚C, the medium was removed, and the precipitate was dissolved in dimethyl sulfoxide (DMSO). The optical density (OD) values were measured at 570 nm using an ELISA reader (Multiskan MK3). The relative cell viability was calculated according to the following formula: Relative cell viability (%) = OD experiment / OD control x 100 (OD blank was considered as zero). The IC 50 was defined as the concentration required to decrease the relative viabilities of cells to 50% of that of the control (no drug) value.
FaDu cell characteristics induced by multidrug resistance
Analysis of the cell growth curve. FaDu and FaDu/T-200 nM cells (10x10 4 /ml) were subcultured in a 96-well cluster, and the OD 570 nm values were measured as described above every 24 h for 6 days. Experiments were repeated three times.
Morphological observation. FaDu, FaDu/T-200 nM and FaDu cells treated with Taxol (200 nM) for 24 h were seeded (15x10 4 / well) in 24-well dishes containing 1 ml culture medium to observe the morphological changes. Cells were washed twice with phosphate-buffered solution (PBS), fixed using 95% alcohol for 10 min, and stained with 0.01% acridine orange for 5 min, or with Hoechst 33342 (10 µg/ml) and propidium iodide (PI) (50 µg/ml) at 37˚C for 30 min. Morphological changes were examined by fluorescence microscopy. Taxol (200 nM) for 24 h were analyzed by flow cytometry. In brief, cells (15x10 4 /ml) were trypsinized and washed with PBS, respectively. Cells were then pelleted by centrifugation at 1000 rpm for 5 min and resuspended at a concentration of 1x10 6 cells/ ml in staining solution (50 µg/ml PI and 100 µg/ml RNase A). After incubation at 4˚C in the dark for 30 min, cells were analyzed using an Epics XL flow cytometer (Beckman Coulter Co., Miami, FL, USA). The proportions of cells at G0/G1, S and G2/M phases were analyzed by the Multicycle software program (Beckman Coulter).
Flow cytometric analysis of cell cycle distribution and apoptosis. The cell cycle distribution and apoptosis in the FaDu, FaDu/T-200 nM and FaDu cells treated with
For assessment of apoptosis, Annexin V-FITC and PI were used. After trypsinization, cells were resuspended in binding buffer (20 µl) containing Annexin V-FITC (5 µl, 20 µg/ml) and PI (10 µl, 20 µg/ml) for at least 10 min at room temperature, and then binding buffer (300 µl) was added before analysis with the System II, version 3.0 (Beckman Coulter).
Reverse transcription-PCR. Total RNA was extracted using TRIzol (Invitrogen). The reverse transcription reaction was performed using the ExScript RT reagent kit (Takara, Dalian, China) in a final volume of 20 µl containing 1 µg total RNA, 4 µl 5X ExScript buffer, 1 µl dNTP mix, 1 µl Oligo(dT) primer, 0.5 µl ExScript RTase, 0.5 µl RNase inhibitor, and RNase-free water to a volume of 20 µl. The reverse transcription reaction was performed at 42˚C for 15 min, and the reaction was terminated by heating at 95˚C for 2 min. PCR was performed following the instructions of Takara Taq™ under the following conditions: pre-degeneration at 95˚C for 3 min, degeneration at 95˚C for 60 sec, renaturation at 58˚C for 45 sec, and elongation at 72˚C for 60 sec, for a total of 25 cycles. All experiments were conducted 3 times. The primers were as follows: MDR1/ ABCB1: forward 5'-CTGCTCAAGTTAAAGGGGCTAT-3' and reverse 5'-AACGGTTCGGAAGTTTTCTATT-3'; BCRP/ ABCG2: forward 5'-GGTCTCAACGCCATCC-3' and reverse 5'-GAGTCTGCCACTTTATCCA-3'.
Western blot analysis. Total protein was extracted using radioimmunoprecipitation buffer (RIPA), a protein lysis buffer, according to standard protocols. The Bradford method was used to determine the protein concentration of the supernatant. Statistics. Data are presented as mean ± standard error of the mean (SEM). Statistical calculations were performed using SPSS16.0 software package. One-way analysis of variance (ANOVA) was applied for the analyses; P-values <0.05 were considered significant.
Results

Establishment of a Taxol-resistant cell line FaDu/T and growth curve analysis.
We established FaDu/T by exposing normal FaDu cells to escalating concentrations of Taxol stepwise for over 12 months. FaDu/T showed a marked change in cellular morphology with many elongated cell dendrites, and slow growth was observed (Fig. 1A) . The growth curves for FaDu and FaDu/T cells are shown in Fig. 1B . The resistant cells grew more slowly than the parental cells (P<0.05).
Cross-resistance profiles of the FaDu/T cells. Chemotherapeutic drugs of different categories including Taxol, Dox, VCR, 5-FU and DDP were used to evaluate the different resistances of the FaDu/T cells. As shown in Table I, the IC 
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Apoptosis of the FaDu and FaDu/T cells induced by Taxol.
Compared with the apoptotic rate of the untreated cells (4.45±1.60%), the rates in the cells exposed to Taxol (200 nM, 24 h) and FaDu/T cells whose tolerance to Taxol was 200 nM were 32.9±2.39 and 4.53±1.1%, respectively (Fig. 4) . These (Fig. 5B ).
Statistical analysis showed that a significant difference existed between the FaDu and FaDu/T cells (P<0.05).
Changes in MDR1/ABCB1 and BCRP/ABCG2 protein levels.
In comparison with the untreated FaDu cells, the expression of MDR1/ABCB1 was up-regulated while that of BCRP/ABCG2 was down-regulated when β-actin was taken as the standard in both the FaDu/T-50 nM and FaDu/T-200 nM cells (Fig. 6A) . (Fig. 6B) . Statistical analysis showed that a significant difference existed between the FaDu and FaDu/T cells (P<0.05).
Caspase-3, Bcl-2 and Bax expression as assessed by Western blotting.
In comparison with the untreated FaDu cells, the expression of caspase-3 and Bax was up-regulated while that of Bcl-2 was down-regulated in both the FaDu/T-50 nM and FaDu/T-200 nM cells when β-actin was used as the standard (Fig. 7A) . Image J software was used to analyze the relative photodensity. Considering the control as 100%, the density ratio of caspase-3, Bcl-2 and Bax was 57.92±6.55, 199.69±29.96 and 89.03±13.56% in the FaDu/T-50 nM and 40.56±7.93, 223.85±45.84 and 53.82±11.17% in the FaDu/T-200 nM cells, respectively (Fig. 7B) . The relative Bcl-2/Bax level was analyzed between the different cells and a significant increase was detected in the FaDu/T cells compared with the control. Considering the control as 1.00, the ratio of Bcl-2/ Bax was 1.87±0.16 in FaDu/T-50 nM and 3.83±0.47 in the FaDu/T-200 nM cells (Fig. 7C) . Statistical analysis showed that a significant difference was achieved between the FaDu and FaDu/T cells (P<0.01). These results further explain the mechanism of anti-apoptosis in FaDu/T cells.
Discussion
The major obstacle to tumor chemotherapy is drug resistance, including intrinsic and acquired resistance to multiple chemotherapeutic drugs, yet the mechanisms responsible for MDR remain unclear (7) . To elucidate the mechanism responsible for MDR is critical. Here, we established a multidrug resistant cell line to Taxol (FaDu/T) by exposing normal FaDu cells to escalating concentrations of Taxol stepwise for over 12 months and investigated the basic characteristics of FaDu/T cells in an effort to provide theoretical support for the study of the reversal of MDR in HNSCC.
Firstly, the multidrug resistance of FaDu/T to DDP, 5-FU, Dox and VCR was assayed by MTT. Results showed varying degrees of resistance, respectively. Morphological changes were then analyzed by microscopic observation using phase contrast microscopy. The MDR cell line FaDu/T grew significantly slower when compared with the parental cells as determined by morphological observation and growth curve analysis. The biological activity of Taxol is based on its ability to promote microtubule assembly and stabilize tubulin polymers against depolymerization. This arrests cells in the G2/M phase, inducing cell apoptosis (consequently, leaving the cells in the G0/G1 phase to survive). This may be the reason for the slower growth rate of FaDu/T cells (8) . Analysis of the cell cycle distribution by flow cytometry revealed an increased proportion of cells in the G0/G1 and G2/M phases in this study, which verified the growth curve analysis.
Upon acridine orange staining and Hoechst 33342/ PI double staining, FaDu/T cells showed powerful apoptosis resistance to Taxol compared with the control cells. Chromosome condensation and nuclear fragmentation were detected under fluorescence microscopy. Quantitative analysis of apoptosis by flow cytometry revealed a similar result, which further confirmed the anti-apoptotic ability of FaDu/T cells. In general, the mechanism of apoptosis induced by Taxol involves Bcl-2, caspase-3, and the Fas/Fas ligand (9) . Expression of caspase-3, Bcl-2 and Bax in FaDu and FaDu/T cells was detected by Western blot analysis in this study, and significant alterations to resist apoptosis were detected. This further proves the anti-apoptosis of the MDR cells.
Many genes have been reported to be related with drug resistance or sensitivity, such as ATP-binding cassette (ABC) genes (10) . The human has 49 ABC genes, arranged in eight subfamilies and named through divergent evolution (11) . The variable expression of ABC transporters results in ATP-driven efflux of antitumor drugs from cancer cells, thereby leading to decreased intracellular drug accumulation and consequent MDR (12) . The main elements related to MDR include P-glycoprotein (P-gp) translated by MDR1/ABCB1, the multidrug-resistance protein (MRP1) and the breast cancer multi-drug resistance protein 1 (BCRP/ABCG2) (13) .
In the present study we focused on MDR1/ABCB1 and BCRP/ABCG2. The overexpression of MDR1/ABCB1 has been reported to be associated with resistance to a wide range of anticancer drugs, including Taxol (14) (15) (16) (17) . Here, we assessed the mRNA and protein levels of MDR1/ABCB1 in the FaDu/T cells, and up-regulation was obviously detected in a dosedependent manner. Yet, there is a disagreement concerning the role of BCRP/ABCG2 during MDR progression and whether or not Taxol is a substrate of ABCG2. Studies have found that Taxol is not the substrate of BCRP/ABCG2 during MDR (18, 19) . They reported, although a mutation at position 482 can alter the substrate specificity of BCRP/ABCG2, Taxol was not the substrate of either wild-type BCRP/ABCG2 or its mutants (20) . Meanwhile, various studies found that BCRP/ABCG2 was involved during MDR induced by Taxol (21, 22) . At the gene and protein levels, we observed a decreased expression of BCRP/ABCG2 in the FaDu/T cells compared with the parental cells. For the first time we report the role of BCRP/ ABCG2 in MDR progression induced by Taxol in FaDu cells. Controversy concerning the relationship between MDR1/ ABCB1 and BCRP/ABCG2 during MDR also exists. A recent study reported the inverse trend of expression between ABCB1 and ABCG2 mRNA at the blood-brain barrier in ABCB1 (-/-) and ABCG2 (-/-) knockout mice (23) . Other studies have also demonstrated an inverse relationship between them (24, 25) . Meanwhile, a positive relationship between MDR1/ABCB1 and BCRP/ABCG2 expression has also been reported (26, 27) . According to RT-PCR and Western blot analysis, we reported that the levels of two transporters in FaDu and FaDu/T cells were MDR1/ABCB1: FaDu<FaDu/T whereas BCRP/ABCG2: FaDu>FaDu/T, respectively. When the cancer cells were exposed to the chemotherapy drugs, due to coexpression, inverse or positive relationships among the ABC transporters have not been particularly investigated. It could be hypothesized that to protect the cells from cytokine-induced oxidative damage, the lack of a specific gene may be offset by expression and protein synthesis of another compensatory gene. The variable expression of ABC transporters may be regulated in an abnormal manner in the presence of an anticancer drug. The mechanism involved in the decreased expression level of BCRP/ABCG2 in FaDu/T cells warrants further studied.
In conclusion, the MDR cell line FaDu/T provides us with a base for the further study of the resistant mechanisms of clinical HNSCC drug resistance. Further study must be carried out on the mechanism involved in the reversed trend of molecular expression between ABCB1 and ABCG2 in FaDu/T cells, which would be valuable for the prevention of MDR in clinical cancer chemotherapy.
